Minerva Neurosciences Overview
Valuation check: NERV's ROE is 1415.46%, above the Healthcare sector average of 21.67%.
Get informed when a big investor buys or sells
+ Follow1415.46%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for NERV is 1415.46%. That is above the Healthcare sector average of 21.67%. Investors often review this figure alongside Minerva Neurosciences's historical trend and sector peers before judging valuation or financial health.
Against Healthcare companies, NERV currently prints 1415.46% for ROE, while the sector average sits near 21.67%. That is roughly 6432.5% above the sector mean. Large gaps often invite a closer look at Minerva Neurosciences's growth, margins, and balance sheet.
Return on Equity shows how effectively Minerva Neurosciences converts resources into returns. At 1415.46%, NERV may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting NERV's ROE (1415.46%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack Minerva Neurosciences's ROE against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.
